Loading stock data…
Jazz Pharmaceuticals plc (JAZZ)
$240.07-6.74 (-2.73%)
Market ClosedLast close Sep 8
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Jazz Pharmaceuticals plc in the Healthcare sector is trading at $240.07 with a market capitalization of $15.6B. Wall Street consensus targets $289.45 (20 analysts), implying a +20.6% move over the next 12 months. The stock is currently near its 52-week high of $266.38, remaining 16.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +20.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.21B↑ | $1.07B↓ | $1.20B↑ | $1.13B↑ | $1.05B |
| Gross Profit | $1.09B↑ | $934.80M↓ | $1.04B↑ | $997.23M↑ | $929.40M |
| Operating Income | $325.20M↓ | $336.60M↑ | $254.53M↑ | $100.01M↓ | $219.00M |
| Net Income | $192.80M↓ | $293.10M↑ | $203.45M↓ | $251.41M↑ | -$718.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$15.58B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
16.43
Beta
Defensive asset. Lower volatility than the S&P 500.
0.36
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.59%
Volume
Today's trading volume
467,902
Recent News
1 Value Stock with Exciting Potential and 2 We Brush Off
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Quoin in line for priority review voucher if rare paediatric drug approved
Quoin has now received two rare paediatric disease designations for its lead asset QRX003.
Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone?
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported that Ziihera plus chemotherapy produced a statistically significant and clinically meaningful overall-survival benefit over trastuzumab plus chemotherapy in the Phase 3 HERIZON-GEA-01 trial. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said the overall-survival hazard ratio improved from the first interim analysis, when the result favored Ziihera but was not statistically significant. The global, […]
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stocks making big moves yesterday: Jazz Pharmaceuticals, SAIC, Herbalife, AGCO, and Deere
Check out the companies making headlines yesterday: